Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Hematol. 2011 Jan;86(1):110-5. doi: 10.1002/ajh.21888.

A reappraisal of Gaucher disease-diagnosis and disease management algorithms.

Author information

  • 1Department of Pediatrics and Medicine, Yale University, New Haven, Connecticut 06562, USA. pramod.mistry@yale.edu

Abstract

Type 1 (non-neuronopathic) Gaucher disease was the first lysosomal storage disorder for which an effective enzyme replacement therapy was developed and it has become a prototype for treatments for related orphan diseases. There are currently four treatment options available to patients with Gaucher disease, nevertheless, almost 25% of Type 1 Gaucher patients do not gain timely access to therapy because of delays in diagnosis after the onset of symptoms. Diagnosis of Gaucher disease by enzyme testing is unequivocal, but the rarity of the disease and nonspecific and heterogeneous nature of Gaucher disease symptoms may impede consideration of this disease in the differential diagnosis. To help promote timely diagnosis and optimal management of the protean presentations of Gaucher disease, a consensus meeting was convened to develop algorithms for diagnosis and disease management for Gaucher disease.

PMID:
21080341
[PubMed - indexed for MEDLINE]
PMCID:
PMC3058841
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk